Stylized representation of the NextPoint logo icon, featuring immunotherapy-related cellular imagery

expanding the potential of immunotherapy

One pathway,
many possibilities

NextPoint’s world renowned scientific founders recently discovered a novel checkpoint axis that is independent of PD-1/L1 and is present at high levels in many hard to treat cancers. This revolutionary discovery represents a previously unknown gateway to modulating both the adaptive and innate immune systems to find and destroy cancer cells.

Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer.

world-class team.

scientific founders.

The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology.

XingXing Zang, PhD

Albert Einstein College of Medicine

Gordon Freeman, PhD

Dana-Farber Cancer Institute


Detlev Biniszkiewicz, PhD

Chief Executive Officer

Scott Chappel, PhD

Chief Scientific Officer

Paul Conrad, PhD, MBA

Chief Business Officer

Briggs Morrison, MD

Interim Chief Medical Officer

investors & partners.

Logo for MPM Capital, powering breakthroughs in life sciences
Logo for Dana-Farber Cancer Institute, Binney Street Capital
Logo for Simcere